Noninvasive monitoring in a patient with SAH diagnosis treated with Cerebrolysin - case report and review of the literature.
Journal
European review for medical and pharmacological sciences
ISSN: 2284-0729
Titre abrégé: Eur Rev Med Pharmacol Sci
Pays: Italy
ID NLM: 9717360
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
medline:
1
8
2023
pubmed:
31
7
2023
entrez:
31
7
2023
Statut:
ppublish
Résumé
Subarachnoid hemorrhage (SAH) causes a high percentage of deaths and rehabilitation failures. Despite endovascular and surgery treatment algorithms, there is still no consensus on the guidelines for monitoring and neuroprotective treatment of patients. We report a case of a patient with SAH treated endovascularly. The patient was hospitalized in the intensive care unit and monitored using Near Infrared Spectroscopy (NIRS) and Optic Nerve Diameters Assessment (ONDS). Early and high-dose Cerebrolysin was used safely as neuroprotective treatment intravenously. The treatment using Cerebrolysin and additional monitoring was beneficial for the patient.
Sections du résumé
BACKGROUND
Subarachnoid hemorrhage (SAH) causes a high percentage of deaths and rehabilitation failures. Despite endovascular and surgery treatment algorithms, there is still no consensus on the guidelines for monitoring and neuroprotective treatment of patients.
CASE REPORT
We report a case of a patient with SAH treated endovascularly. The patient was hospitalized in the intensive care unit and monitored using Near Infrared Spectroscopy (NIRS) and Optic Nerve Diameters Assessment (ONDS).
CONCLUSIONS
Early and high-dose Cerebrolysin was used safely as neuroprotective treatment intravenously. The treatment using Cerebrolysin and additional monitoring was beneficial for the patient.
Identifiants
pubmed: 37522695
doi: 10.26355/eurrev_202307_33155
pii:
doi:
Substances chimiques
cerebrolysin
37KZM6S21G
Amino Acids
0
Types de publication
Review
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM